|
Alternative names, keywords |
|
|
Samples required |
● Clotted blood (gold cap, 5 mL tube). |
|
Test indications |
See NICE guideline NG12 Suspected cancer: recognition and referral and NICE guidance CG122 Ovarian cancer: the recognition and initial management of ovarian cancer for use in primary care. |
|
Factors affecting test performance/ results |
Biotin may interfere - samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration. In rare cases, interference due to extremely high titres of antibodies to analyte-specific antibodies, streptavidin or ruthenium can occur. Results should always be assessed in conjunction with the patient’s medical history, clinical examination and other findings. |
|
Reference range |
up to 35 KU/L See NICE NG12 for age-related thresholds. CA 125 is not specific for ovarian malignancy and may be increased in many conditions including liver disease, ascites, during menstruation, endometriosis, any peritoneal inflammation, and in other malignancies. |
|
Turnaround time |
3 days |
|
Enquiries |
Biochemistry (Automation) |